Bank of America’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-86,796
| Closed | -$833K | – | 8712 |
|
|
2024
Q4 | $833K | Sell |
86,796
-30,547
| -26% | -$159K | ﹤0.01% | 5185 |
|
|
2024
Q3 | $336K | Buy |
117,343
+23,049
| +24% | +$71.3K | ﹤0.01% | 5732 |
|
|
2024
Q2 | $275K | Sell |
94,294
-90,072
| -49% | -$246K | ﹤0.01% | 5720 |
|
|
2024
Q1 | $588K | Sell |
184,366
-53,254
| -22% | -$178K | ﹤0.01% | 5253 |
|
|
2023
Q4 | $798K | Sell |
237,620
-104,851
| -31% | -$270K | ﹤0.01% | 5148 |
|
|
2023
Q3 | $815K | Buy |
342,471
+10,445
| +3% | +$21.9K | ﹤0.01% | 4966 |
|
|
2023
Q2 | $584K | Buy |
332,026
+79,878
| +32% | +$204K | ﹤0.01% | 5172 |
|
|
2023
Q1 | $777K | Buy |
252,148
+233,452
| +1,249% | +$1.4M | ﹤0.01% | 5075 |
|
|
2022
Q4 | $99.1K | Sell |
18,696
-7,587
| -29% | -$34.7K | ﹤0.01% | 6240 |
|
|
2022
Q3 | $92K | Buy |
26,283
+3,484
| +15% | +$11.5K | ﹤0.01% | 6387 |
|
|
2022
Q2 | $59K | Sell |
22,799
-8,950
| -28% | -$24.9K | ﹤0.01% | 6758 |
|
|
2022
Q1 | $143K | Sell |
31,749
-1,574
| -5% | -$7.1K | ﹤0.01% | 6667 |
|
|
2021
Q4 | $227K | Buy |
33,323
+4,088
| +14% | +$27.8K | ﹤0.01% | 6430 |
|
|
2021
Q3 | $213K | Buy |
29,235
+3,384
| +13% | +$29K | ﹤0.01% | 6266 |
|
|
2021
Q2 | $259K | Buy |
25,851
+10,534
| +69% | +$94.3K | ﹤0.01% | 5916 |
|
|
2021
Q1 | $146K | Buy |
15,317
+8,714
| +132% | +$85.5K | ﹤0.01% | 6235 |
|
|
2020
Q4 | $72K | Sell |
6,603
-3,967
| -38% | -$41.8K | ﹤0.01% | 6149 |
|
|
2020
Q3 | $93K | Buy |
+10,570
| New | +$120K | ﹤0.01% | 5747 |
|
Other funds holding PSTX
Bank of America's PSTX Position: Q1 2025 in Review
Bank of America sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2025, closing a stake of 86,796 shares — an estimated $833K sold.
Bank of America first reported a position in PSTX in Q3 2020 and held it in 18 quarters. The position peaked at $833K in Q4 2024. 1 fund tracked by Wall St. Rank holds PSTX as of Q1 2025.
- Bank of America reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
- Bank of America sold 86,796 Poseida Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $833K.
- Bank of America first reported a position in Poseida Therapeutics, Inc. Common Stock in Q3 2020 and held it in 18 quarters.
- Bank of America's Poseida Therapeutics, Inc. Common Stock position peaked at $833K in Q4 2024.
- 1 fund tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2025.
Based on Bank of America's 13F filing for Q1 2025, filed 15 May 2025.